首页> 外国专利> Composition of sustained Release injection intramuscularly, comprising a Drug, a biocompatible based Copolymer of lactic acid and Glycolic Acid, with a Molecular weight between 30 and 46 kDa and an inherent viscosity between 0.25 and 0.31 g / dl, and DMSO as Solvent Kit; pharmacist; And Method for its preparation.

Composition of sustained Release injection intramuscularly, comprising a Drug, a biocompatible based Copolymer of lactic acid and Glycolic Acid, with a Molecular weight between 30 and 46 kDa and an inherent viscosity between 0.25 and 0.31 g / dl, and DMSO as Solvent Kit; pharmacist; And Method for its preparation.

机译:肌内缓释注射剂的组合物,其包含药物,分子量为30至46 kDa,比浓对数粘度为0.25至0.31 g / dl的乳酸和乙醇酸的生物相容性共聚物,以及DMSO作为溶剂套件;药剂师;及其制备方法。

摘要

The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.
机译:本发明涉及适于在体内形成原位固体植入物的可注射的肌内储库组合物,其包含利培酮和/或帕潘立酮或其任何可药用盐的任何组合的药物,基于乳酸的生物相容性共聚物和具有约50:50的乳酸与乙醇酸的单体比例的乙醇酸和DMSO溶剂,其中该组合物立即起效并连续至少4周释放药物,并且其中该组合物在体内具有药代动力学特性因此适合每4周甚至更长的时间服用。

著录项

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号